Kostandinos Sideras

Assistant Professor

Mayo Clinic
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Kostandinos Sideras is an Assistant Professor at Mayo Clinic in the United States. His research primarily focuses on breast cancer, pancreatic cancer, and the immune microenvironment in various oncological contexts. Recent articles authored by Dr. Sideras include studies on the efficacy of pembrolizumab in triple-negative breast cancer and the impact of type I interferons on pancreatic malignancies.

Articles (24)

Purpose: Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer. Previous studies demonstrated that inhibition of the MAPK pathway with a MEK inhibitor is synergistic with immune checkpoint inhibitors. Patients and Methods: We conducted a phase I/II trial of pembrolizumab and binimetinib in patients with metastatic triple-negative breast cancer with ≤3 prior lines of therapy. There were two dose levels (DL) with binimetinib at 45 mg at DL 0 and 30 mg at DL −1. Results: The recommended phase II dose was the standard dose of pembrolizumab with binimetinib 30 mg twice daily. The objective response rate (ORR) was 30.4%, with a numerically higher ORR in patients without liver metastasis at 45.5%. Among patients who achieved objective responses, 80% had a duration of response >12 months and ongoing even after stopping treatment (5.4–69.0 months). Patients with PD-L1–positive tumors (modified proportion score ≥10) were more likely to respond with an ORR of 66.7%. However, clinical benefit was observed in 25% of patients with PD-L1–negative tumors. Consistent with preclinical studies, four of six patients with clinical benefit had either increased PD-L1 or decreased p-ERK expressions in serial circulating cancer-associated macrophage-like cells after starting binimetinib. Conclusions: Pembrolizumab and binimetinib at 30 mg are safe with manageable toxicities. Promising activity was observed in patients without liver metastases. Future larger clinical trials are warranted to further evaluate the efficacy of this chemotherapy-free combination.

Year:

2025

Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocrine therapy-based treatment.

Year:

2025

Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no)

Year:

2025

Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negative, HER2-positive and triple-negative tumors.

Year:

2025

Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no).

Year:

2025

Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/hormone receptor-negative tumors. Survival time is given as time since baseline CTC assessment in months. The P-values refers to the global log rank test with 3 degrees of freedom.

Year:

2025

Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is given as time since baseline CTC assessment in months. (A, C) cutoff for CTC positivity ≥1 CTC; (B, D) cutoff for CTC positivity ≥5 CTCs. The P-values refer to pairwise comparisons with the log rank test.

Year:

2025

Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time since baseline CTC assessment in months. (A, D) hormone receptor-positive/HER2-negative tumors; (B, E) HER2- positive tumors; (C, F) triple-negative tumors. The P-values refer to pairwise comparisons with the log rank test.

Year:

2025

Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according to treatment type.

Year:

2025

Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being a CTC responder are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC responder (yes vs no).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (28)

Keith Knutson

Mayo Clinic Florida

UNITED STATES
View details

Catherine Alix-Panabières

Director/Professor

University Hospital of Montpellier

FRANCE
View details

Paola Gazzaniga

Sapienza University of Rome

ITALY
View details

Daniel F. Hayes

Stuart B. Padnos Professor of Breast Cancer Research

University of Michigan Rogel Cancer Center

UNITED STATES
View details

Michail Ignatiadis

Leader Investigator Initiated Trials

Institut Jules Bordet

BELGIUM
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Zeruesenay Desta

Professor of Medicine

Indiana University

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Matthew Goetz

Professor of Oncology and Pharmacology

Mayo Clinic

UNITED STATES
View details

Jean-Yves Pierga

Head of Department

Institut Curie

FRANCE
View details

Karthik Giridhar

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Tanja Fehm

Professor

University Hospital Düsseldorf

GERMANY
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Ravinder Singh

Professor

Mayo Clinic

UNITED STATES
View details

Leon W. M. M. Terstappen

University of Twente

NETHERLANDS
View details

Elisabetta Munzone

Director

European Institute of Oncology

ITALY
View details

Justin Stebbing

Professor

Imperial College London

UNITED KINGDOM
View details

Evi Lianidou

PROFESSOR

National and Kapodistrian University of Athens

GREECE
View details

James Ingle

Mayo Clinic Rochester

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Saranya Chumsri

Professor of Oncology

Mayo Clinic Florida

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Klaus Pantel

-

GERMANY
View details

Markus Wallwiener

University Hospital Heidelberg

GERMANY
View details

DANIELE GENERALI

University of Trieste

ITALY
View details